{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:46:55Z","timestamp":1786985215300,"version":"build-2736575974"},"reference-count":97,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100009403","name":"Menofia\u00a0University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009403","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.bioorg.2026.109476","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T16:43:30Z","timestamp":1767804210000},"page":"109476","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Expanding the chemical and therapeutic landscape of 5H-Indeno[1,2-b]pyridin-5-one derivatives: Novel anticancer activity, EGFR inhibition, and modulation of HIF\u2013VEGF and PI3K\/AKT\/mTOR pathways supported by computational insights"],"prefix":"10.1016","volume":"170","author":[{"given":"Hagar S.","family":"El-Hema","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadeer A.","family":"El-Shazly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A.","family":"Hawata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabil M.","family":"Yousif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Modather F.","family":"Hussein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A.","family":"Said","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esraa A.","family":"Aidy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitham E.","family":"Shehata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adel A.-H.","family":"Abdel-Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2026.109476_bb0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bioorg.2026.109476_bb0010","first-page":"10","article-title":"Cancer statistics, 2025, CA Cancer","volume":"75","author":"Siegel","year":"2025","journal-title":"J. Clin."},{"key":"10.1016\/j.bioorg.2026.109476_bb0015","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bioorg.2026.109476_bb0020","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/nrc3599","article-title":"Cancer drug resistance: an evolving paradigm","volume":"13","author":"Holohan","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bioorg.2026.109476_bb0025","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s12032-022-01677-0","article-title":"Innovation in cancer therapeutics and regulatory perspectives","volume":"39","author":"Sharma","year":"2022","journal-title":"Med. Oncol."},{"key":"10.1016\/j.bioorg.2026.109476_bb0030","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1007\/s00018-008-8111-5","article-title":"An overview of cancer multidrug resistance: a still unsolved problem","volume":"65","author":"Lage","year":"2008","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.bioorg.2026.109476_bb0035","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41392-024-01856-7","article-title":"Exploring treatment options in cancer: tumor treatment strategies","volume":"9","author":"Liu","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bioorg.2026.109476_bb0040","doi-asserted-by":"crossref","first-page":"1593380","DOI":"10.3389\/fphar.2025.1593380","article-title":"Based on small molecules: development and application of fibroblast activation protein inhibitors radiopharmaceutical in tumor precision therapy","volume":"16","author":"Luo","year":"2025","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.109476_bb0045","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1039\/D4MD00246F","article-title":"Design, synthesis and biological evaluation of a novel PSMA\u2013PI3K small molecule drug conjugate","volume":"15","author":"Peng","year":"2024","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109476_bb0050","article-title":"Applications of innovative synthetic strategies in anticancer drug discovery: the driving force of new chemical reactions","volume":"93","author":"Wang","year":"2025","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.109476_bb0055","first-page":"2025","volume":"10","author":"Matthius","year":"2025","journal-title":"Experts Forecast Cancer Research and Treatment Advances in"},{"key":"10.1016\/j.bioorg.2026.109476_bb0060","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41392-021-00572-w","article-title":"Small molecules in targeted cancer therapy: advances, challenges, and future perspectives","volume":"6","author":"Zhong","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bioorg.2026.109476_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2025.143790","article-title":"Novel pyrimidopyridothiazine-based derivatives as potential anticancer and antibacterial agents: a step towards design and synthesis of multi-targeted therapeutics","volume":"1349","author":"El-Hema","year":"2026","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.bioorg.2026.109476_bb0070","doi-asserted-by":"crossref","first-page":"27992","DOI":"10.1038\/s41598-025-12140-1","article-title":"Design, antiproliferative potency, and in silico studies of novel (5-methylfuran-3-ylthio)-3-phenylquinazolin-4(3H)-one-based derivatives as potential EGFR inhibitors","volume":"15","author":"Soliman","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2026.109476_bb0075","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.3390\/ph18101472","article-title":"Innovative amino-functionalization of pyrido[2,3-d]pyrimidine scaffolds for broad therapeutic applications supported by computational analyses","volume":"18","author":"El-Hema","year":"2025","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.bioorg.2026.109476_bb0080","doi-asserted-by":"crossref","first-page":"508","DOI":"10.18632\/oncotarget.28747","article-title":"Challenges and resistance mechanisms to EGFR-targeted therapies in head and neck cancers and breast cancer: insights into RTK-dependent and independent mechanisms","volume":"16","author":"Shyamsunder","year":"2025","journal-title":"Oncotarget"},{"key":"10.1016\/j.bioorg.2026.109476_bb0085","series-title":"StatPearls [Internet], StatPearls Publishing","article-title":"Biochemistry, epidermal growth factor receptor","author":"Murphrey","year":"2023"},{"key":"10.1016\/j.bioorg.2026.109476_bb0090","doi-asserted-by":"crossref","first-page":"12937","DOI":"10.3390\/ijms222312937","article-title":"EGFR transgene stimulates spontaneous formation of MCF7 breast cancer cell spheroids with partial loss of HER3 receptor","volume":"22","author":"Troitskaya","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2026.109476_bb0095","doi-asserted-by":"crossref","first-page":"8455","DOI":"10.1007\/s00432-023-04750-x","article-title":"Tumor suppressor miR-218 directly targets epidermal growth factor receptor (EGFR) expression in triple-negative breast cancer, sensitizing cells to irradiation","volume":"149","author":"Wischmann","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2026.109476_bb0100","article-title":"EGFR as a therapeutic target to develop new generation tyrosine kinase inhibitors against breast cancer: a critical review","volume":"7","author":"Raju","year":"2024","journal-title":"Results Chem."},{"key":"10.1016\/j.bioorg.2026.109476_bb0105","doi-asserted-by":"crossref","first-page":"31784","DOI":"10.1021\/acsomega.3c02799","article-title":"Machine learning-based approach to developing potent EGFR inhibitors for breast cancer: design, synthesis, and in vitro evaluation","volume":"8","author":"Nada","year":"2023","journal-title":"ACS Omega"},{"key":"10.1016\/j.bioorg.2026.109476_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.108106","article-title":"Exploring 1,2,3-triazole-Schiff\u2019s base hybrids as innovative EGFR inhibitors for the treatment of breast cancer: in vitro and in silico study","volume":"155","author":"Nawareg","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.109476_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116607","article-title":"Novel dihydropyrimidines as promising EGFR and HER2 inhibitors: insights from experimental and computational studies","volume":"275","author":"Faizan","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109476_bb0120","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.semcancer.2022.04.002","article-title":"EGFR signaling pathway as a therapeutic target in human cancers","volume":"85","author":"Levantini","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.bioorg.2026.109476_bb0125","doi-asserted-by":"crossref","first-page":"297","DOI":"10.37349\/etat.2022.00084","article-title":"In vitro breast cancer models for studying mechanisms of resistance to endocrine therapy","volume":"3","author":"Cheng","year":"2022","journal-title":"Explor. Target. Anti-Tumor Ther."},{"key":"10.1016\/j.bioorg.2026.109476_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2022.188789","article-title":"Can EGFR be a therapeutic target in breast cancer?","volume":"1877","author":"Li","year":"2022","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.bioorg.2026.109476_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2022.134848","article-title":"Design, synthesis, analysis, evaluation of cytotoxicity against MCF-7 breast cancer cells, 3D QSAR studies and EGFR, HER2 inhibition studies on novel Biginelli 1,4-dihydropyrimidines","volume":"1277","author":"Naishima","year":"2023","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.bioorg.2026.109476_bb0140","doi-asserted-by":"crossref","first-page":"7065","DOI":"10.3390\/ijms26157065","article-title":"Design, synthesis, and anticancer evaluation of new small-molecule EGFR inhibitors targeting NSCLC and breast cancer","volume":"26","author":"Sever","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2026.109476_bb0145","article-title":"Novel triazole-urea hybrids as promising EGFR inhibitors: synthesis, molecular modeling and antiproliferative activity studies against breast cancer","volume":"143367","author":"T\u00fcre","year":"2025","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.bioorg.2026.109476_bb0150","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.3390\/cancers17162606","article-title":"From structure to function: the impact of EGFR and IGF-IR in 3D breast cancer spheroids","volume":"17","author":"Gourdoupi","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.bioorg.2026.109476_bb0155","doi-asserted-by":"crossref","first-page":"1384832","DOI":"10.3389\/fchem.2024.1384832","article-title":"3D computer modeling of inhibitors targeting the MCF-7 breast cancer cell line","volume":"12","author":"Zarougui","year":"2024","journal-title":"Front. Chem."},{"key":"10.1016\/j.bioorg.2026.109476_bb0160","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.3390\/ijms24032651","article-title":"Small molecule EGFR inhibitors as anti-cancer agents: discovery, mechanisms of action, and opportunities","volume":"24","author":"Zubair","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2026.109476_bb0165","doi-asserted-by":"crossref","first-page":"4593","DOI":"10.1038\/s41598-024-81704-4","article-title":"Real-world data of dacomitinib as first-line treatment for patients with EGFR-mutant non-small-cell lung cancer","volume":"15","author":"Shin","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2026.109476_bb0170","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/j.cllc.2019.09.006","article-title":"Durable responses to afatinib as first-line therapy for HER2-mutated metastatic non\u2013small-cell lung cancer","volume":"21","author":"Al-Obeidi","year":"2020","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.bioorg.2026.109476_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.amolm.2025.100069","article-title":"Novel combination therapy of osimertinib and Tupichinol E in triple-negative breast cancer: targeting EGFR and CDK4\/6 pathways","volume":"5","author":"Samantaray","year":"2025","journal-title":"Aspects Mol. Med."},{"key":"10.1016\/j.bioorg.2026.109476_bb0180","first-page":"1080","article-title":"Combination of osimertinib with concurrent chemotherapy and hormonal therapy for synchronous NSCLC, hormone receptor-positive breast cancer, and triple-negative breast cancer: case report, case rep","volume":"16","author":"Park","year":"2023","journal-title":"Oncol"},{"key":"10.1016\/j.bioorg.2026.109476_bb0185","doi-asserted-by":"crossref","first-page":"1442237","DOI":"10.3389\/fonc.2024.1442237","article-title":"Targeting non-coding RNAs to overcome osimertinib resistance in EGFR-mutated non-small cell lung cancer","volume":"14","author":"Zeng","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bioorg.2026.109476_bb0190","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.21037\/jtd.2019.08.30","article-title":"Mechanisms of resistance to osimertinib","volume":"12","author":"Lazzari","year":"2020","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.bioorg.2026.109476_bb0195","doi-asserted-by":"crossref","first-page":"3929","DOI":"10.21037\/tcr-24-406","article-title":"Fourth-generation epidermal growth factor receptor-tyrosine kinase inhibitors: hope and challenges","volume":"13","author":"Su","year":"2024","journal-title":"Transl. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.109476_bb0200","article-title":"Exploring 4th generation EGFR inhibitors: a review of clinical outcomes and structural binding insights","volume":"177608","author":"Tariq","year":"2025","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.109476_bb0205","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1080\/14728222.2023.2218613","article-title":"Targeting the EGFR signaling pathway in cancer therapy: what\u2019s new in 2023?","volume":"27","author":"Halder","year":"2023","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.bioorg.2026.109476_bb0210","doi-asserted-by":"crossref","first-page":"4463","DOI":"10.1021\/acs.jmedchem.3c01115","article-title":"Synthesis of Sorafenib\u2013Ruthenium complexes, investigation of biological activities and applications in drug delivery systems as an anticancer agent","volume":"67","author":"Zengin Kurt","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109476_bb0215","doi-asserted-by":"crossref","first-page":"7","DOI":"10.7314\/APJCP.2014.15.7.3185","article-title":"Investigation of antitumor effects of sorafenib and lapatinib alone and in combination on MCF-7 breast cancer cells","volume":"15","author":"Kacan","year":"2014","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/j.bioorg.2026.109476_bb0220","doi-asserted-by":"crossref","first-page":"4955","DOI":"10.1158\/0008-5472.CAN-11-0898","article-title":"Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells","volume":"71","author":"Bareford","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2026.109476_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110319","article-title":"Regorafenib suppresses epidermal growth factor receptor signaling-modulated progression of colorectal cancer","volume":"128","author":"Liu","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bioorg.2026.109476_bb0230","doi-asserted-by":"crossref","DOI":"10.1590\/s2175-979020200004181122","article-title":"Regorafenib suppresses migration of and induces cell cycle arrest and apoptosis in MCF-7 cells","volume":"57","author":"Wang","year":"2021","journal-title":"Braz. J. Pharm. Sci."},{"key":"10.1016\/j.bioorg.2026.109476_bb0235","doi-asserted-by":"crossref","first-page":"1464610","DOI":"10.3389\/fmed.2024.1464610","article-title":"EGFR bypass activation mediates acquired resistance to regorafenib in hepatocellular carcinoma","volume":"11","author":"Hu","year":"2024","journal-title":"Front. Med. (Lausanne)"},{"key":"10.1016\/j.bioorg.2026.109476_bb0240","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1080\/09553002.2020.1730012","article-title":"Regorafenib sensitizes human breast cancer cells to radiation by inhibiting multiple kinases and inducing DNA damage","volume":"97","author":"Mehta","year":"2021","journal-title":"Int. J. Radiat. Biol."},{"key":"10.1016\/j.bioorg.2026.109476_bb0245","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41420-023-01338-9","article-title":"Regorafenib induces Bim-mediated intrinsic apoptosis by blocking AKT-mediated FOXO3a nuclear export","volume":"9","author":"Sun","year":"2023","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.bioorg.2026.109476_bb0250","series-title":"Profile of neratinib and its potential in the treatment of breast cancer, breast Cancer (dove med. Press)","first-page":"147","volume":"7","author":"Feldinger","year":"2015"},{"key":"10.1016\/j.bioorg.2026.109476_bb0255","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.3892\/or.2015.4116","article-title":"Differential effect of EGFR inhibitors on tamoxifen-resistant breast cancer cells","volume":"34","author":"Kim","year":"2015","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.bioorg.2026.109476_bb0260","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1038\/s41416-024-02665-z","article-title":"Neratinib could be effective as monotherapy or in combination with trastuzumab in HER2-low breast cancer cells and organoid models","volume":"130","author":"Arshad","year":"2024","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bioorg.2026.109476_bb0265","article-title":"EGFR as therapeutic target to develop new generation tyrosine kinase inhibitors against breast cancer: a critical review","volume":"7","author":"Raju","year":"2024","journal-title":"Results Chem."},{"key":"10.1016\/j.bioorg.2026.109476_bb0270","article-title":"Photosensitive smart hydrogel loaded neratinib for NIR-triggered photodynamic treatment for improved chemotherapy in breast cancers\u2014in vitro and in vivo analysis","volume":"104016","author":"Xiang","year":"2025","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.bioorg.2026.109476_bb0275","series-title":"Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy, Academic Press","first-page":"1","article-title":"EGFR and HER2 inhibitors as sensitizing agents for cancer chemotherapy","author":"Barbuti","year":"2019"},{"key":"10.1016\/j.bioorg.2026.109476_bb0280","doi-asserted-by":"crossref","first-page":"1396605","DOI":"10.3389\/fphar.2024.1396605","article-title":"Marine-derived EGFR inhibitors: novel compounds targeting breast cancer growth and drug resistance","volume":"15","author":"Li","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.109476_bb0285","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1517\/14712590902735795","article-title":"Mechanisms of tumor resistance to EGFR-targeted therapies","volume":"13","author":"Hopper-Borge","year":"2009","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.bioorg.2026.109476_bb0290","doi-asserted-by":"crossref","first-page":"3066","DOI":"10.3390\/ijms25053066","article-title":"Combination treatment with EGFR inhibitor and doxorubicin synergistically inhibits proliferation of MCF-7 cells and MDA-MB-231 triple-negative breast cancer cells in vitro","volume":"25","author":"Abrahams","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2026.109476_bb0295","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1021\/jm020241c","volume":"46","author":"Wissner","year":"2003","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109476_bb0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105200","article-title":"Design, synthesis and anticancer evaluation of new 4-anilinoquinoline-3-carbonitrile derivatives as dual EGFR\/HER2 inhibitors and apoptosis inducers","volume":"114","author":"Zou","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.109476_bb0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.104794","article-title":"Development of adamantane scaffold containing 1,3,4-thiadiazole derivatives: design, synthesis, anti-proliferative activity and molecular docking study targeting EGFR","volume":"110","author":"Wassel","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.109476_bb0310","first-page":"57","article-title":"Design, synthesis, cytotoxicity, and docking study of new pyrano[3,2\u2013c]pyridine-based derivatives, Azhar int","volume":"5","author":"Mousa","year":"2025","journal-title":"J. Pharm. Med. Sci."},{"key":"10.1016\/j.bioorg.2026.109476_bb0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106874","article-title":"New 2-alkoxycyanopyridine derivatives as inhibitors of EGFR, HER2, and DHFR: synthesis, anticancer evaluation, and molecular modeling studies","volume":"141","author":"Hawas","year":"2023","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.109476_bb0320","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1002\/jps.2600671012","article-title":"Heterocyclic tricycles as potential CNS agents I: 4-aminoalkylindeno[1,2-c]pyrazoles","volume":"67","author":"Lemke","year":"1978","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.bioorg.2026.109476_bb0325","first-page":"1","article-title":"Graph theoretical analysis, pharmacoinformatics and molecular docking investigation of chalcone\u2013Schiff base hybrids as cyclin-dependent kinase inhibitors","volume":"14","author":"Sekar","year":"2024","journal-title":"Res. Pharm."},{"key":"10.1016\/j.bioorg.2026.109476_bb0330","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.bmcl.2007.10.084","article-title":"Discovery of indenopyrazoles as EGFR and VEGFR-2 tyrosine kinase inhibitors by in silico high-throughput screening","volume":"18","author":"Usui","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.109476_bb0335","doi-asserted-by":"crossref","first-page":"19645","DOI":"10.1021\/acsomega.3c01195","article-title":"Sulfonylated indeno[1,2-c]quinoline derivatives as potent EGFR tyrosine kinase inhibitors","volume":"8","author":"Hengphasatporn","year":"2023","journal-title":"ACS Omega"},{"key":"10.1016\/j.bioorg.2026.109476_bb0340","doi-asserted-by":"crossref","first-page":"485","DOI":"10.3390\/molecules27020485","article-title":"A new series of indeno[1,2-c]pyrazoles as EGFR TK inhibitors for NSCLC therapy","volume":"27","author":"\u00d6zdemir","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2026.109476_bb0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2023.136692","article-title":"The anti-breast cancer activity of indeno[1,2-b]pyridin-5-one and their hydrazonal precursors endowed with anti-CDK2 enzyme activity","volume":"1295","author":"Al-Hussain","year":"2024","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.bioorg.2026.109476_bb0350","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.202100092","article-title":"Synthesis of 5H-indeno[1,2-b]pyridine derivatives: antiproliferative and antimetastatic activities against two human prostate cancer cell lines","volume":"354","author":"Charris","year":"2021","journal-title":"Arch. Pharm. (Weinheim)"},{"key":"10.1016\/j.bioorg.2026.109476_bb0355","first-page":"1429","article-title":"Novel candidates synthesis of indenopyrazole, indenoazine and indenothiophene, with anticancer and in silico studies, future","volume":"16","author":"Abdellattif","year":"2024","journal-title":"Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109476_bb0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.arabjc.2023.104569","article-title":"Discovery of novel indene-based hybrids as breast cancer inhibitors targeting Hsp90: synthesis, bio-evaluation and molecular docking study","volume":"16","author":"Alosaimy","year":"2023","journal-title":"Arab. J. Chem."},{"key":"10.1016\/j.bioorg.2026.109476_bb0365","first-page":"1503","article-title":"Convenient synthesis of new indeno[1,2-b]pyridine derivatives for antimicrobial and antioxidant evaluation","volume":"64","author":"Kotb","year":"2021","journal-title":"Egypt. J. Chem."},{"key":"10.1016\/j.bioorg.2026.109476_bb0370","doi-asserted-by":"crossref","first-page":"27367","DOI":"10.1038\/s41598-025-08370-y","article-title":"Computational studies on structural aspects of pyrazolo[3,4-b]pyridine derivatives as TRKA inhibitors in cancer therapy","volume":"15","author":"Gheidari","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2026.109476_bb0375","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1080\/14328917.2016.1265249","article-title":"Growth of ethyl 2-cyano 3-(4-(dimethylamino)phenyl)acrylate single crystal and its structural, optical, thermal and electrical characterisations","volume":"21","author":"Kotteswaran","year":"2017","journal-title":"Mater. Res. Innov."},{"key":"10.1016\/j.bioorg.2026.109476_bb0380","first-page":"262","article-title":"Condensation reactions of aromatic aldehydes with active methylene compounds: the beneficial synergy of alkaline ionic liquid in one-pot synthesis","volume":"9","author":"Bankar","year":"2022","journal-title":"Bentham Sci."},{"key":"10.1016\/j.bioorg.2026.109476_bb0385","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0313064","article-title":"Versatile properties of Opuntia ficus-indica (L.) mill. Flowers: in vitro exploration of antioxidant, antimicrobial, and anticancer activities, network pharmacology analysis, and in-silico molecular docking simulation","volume":"19","author":"Mwaheb","year":"2024","journal-title":"PloS One"},{"key":"10.1016\/j.bioorg.2026.109476_bb0390","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1517\/14728222.11.4.463","article-title":"The epidermal growth factor receptor in malignant gliomas: pathogenesis and therapeutic implications","volume":"11","author":"Nakamura","year":"2007","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.bioorg.2026.109476_bb0395","series-title":"Checkpoint Controls and Cancer","first-page":"301","article-title":"Analysis of cell cycle by flow cytometry","volume":"vol. 2","author":"Pozarowski","year":"2004"},{"key":"10.1016\/j.bioorg.2026.109476_bb0400","doi-asserted-by":"crossref","DOI":"10.1016\/j.algal.2024.103624","article-title":"Biochemical and molecular docking-based assessment of Spirulina platensis's bioactive constituents for their potential application as natural anticancer drug","volume":"82","author":"Khalil","year":"2024","journal-title":"Algal Res."},{"key":"10.1016\/j.bioorg.2026.109476_bb0405","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1465-9921-10-27","article-title":"Vascular endothelial growth factor (VEGF) isoform expression and activity in human and murine lung injury","volume":"10","author":"Medford","year":"2009","journal-title":"Respir. Res."},{"key":"10.1016\/j.bioorg.2026.109476_bb0410","article-title":"Hypoxic preconditioning with cobalt of bone marrow mesenchymal stem cells improves cell migration and enhances therapy for treatment of ischemic acute kidney injury","volume":"8","author":"Yu","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.bioorg.2026.109476_bb0415","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/nprot.2008.73","article-title":"Analyzing real-time PCR data by the comparative CT method","volume":"3","author":"Schmittgen","year":"2008","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.bioorg.2026.109476_bb0420","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1080\/10406638.2024.2403544","article-title":"Molecular investigations of novel pyrano[2,3-c]pyrazole congeners as potential HCoV-229E inhibitors: synthesis, molecular modeling, 3D QSAR, and ADMET screening","volume":"45","author":"Abouelenein","year":"2025","journal-title":"Polycycl. Aromat. Compd."},{"key":"10.1016\/j.bioorg.2026.109476_bb0425","doi-asserted-by":"crossref","first-page":"328","DOI":"10.3390\/md22070328","article-title":"Combining in vitro, in vivo, and network pharmacology assays to identify targets and molecular mechanisms of spirulina-derived biomolecules against breast cancer","volume":"22","author":"Hassanin","year":"2024","journal-title":"Mar. Drugs"},{"key":"10.1016\/j.bioorg.2026.109476_bb0430","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2021.105744","article-title":"Importance of glutamine 189 flexibility in SARS-CoV-2 main protease: lesson learned from in silico virtual screening of ChEMBL database and molecular dynamics","volume":"160","author":"Said","year":"2021","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.bioorg.2026.109476_bb0435","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2024.118053","article-title":"Exploring the antiproliferative and proapoptotic activities of new pyridopyrimidine derivatives and their analogs","volume":"118","author":"Ali","year":"2025","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109476_bb0440","doi-asserted-by":"crossref","first-page":"421","DOI":"10.3390\/ph18030421","article-title":"Enhanced intranasal delivery of atorvastatin via superparamagnetic iron-oxide-loaded nanocarriers: cytotoxicity and inflammation evaluation and in vivo, in silico, and network pharmacology study for targeting glioblastoma management","volume":"18","author":"Attalla","year":"2025","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.bioorg.2026.109476_bb0445","article-title":"Molecular docking and computational assessment of spectroscopic analysis of ethyl 3-(4-chloro-2-methylphenylamino)-3-phenylacrylate as a potential antibacterial agent","volume":"49","author":"Habibi","year":"2025","journal-title":"New J. Chem."},{"key":"10.1016\/j.bioorg.2026.109476_bb0450","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-00427-2","article-title":"Comparative phytochemical and biological evaluation of Egyptian Swinglea glutinosa stems and leaves","volume":"15","author":"Mekky","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2026.109476_bb0455","doi-asserted-by":"crossref","first-page":"110","DOI":"10.21608\/ejs.2025.366425.1061","article-title":"An overview for beginners on density functional theory in computational materials science and some of the related software packages","volume":"47","author":"Abu Radia","year":"2025","journal-title":"Egypt. J. Solids"},{"key":"10.1016\/j.bioorg.2026.109476_bb0460","doi-asserted-by":"crossref","first-page":"6219","DOI":"10.3390\/molecules27196219","article-title":"Development of novel pyridine-thiazole hybrid molecules as potential anticancer agents","volume":"27","author":"Ivasechko","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2026.109476_bb0465","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/pros.2990120112","article-title":"Application of the MTT assay to human prostate cancer cell lines in vitro: establishment of test conditions and assessment of hormone-stimulated growth and drug-induced cytostatic and cytotoxic effects","volume":"12","author":"Romijn","year":"1988","journal-title":"Prostate"},{"key":"10.1016\/j.bioorg.2026.109476_bb0470","first-page":"519","article-title":"Anticancer pyridines induce G2\/M arrest and apoptosis via p53 and JNK upregulation in liver and breast cancer cells","volume":"39","author":"Androutsopoulos","year":"2018","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.bioorg.2026.109476_bb0475","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1080\/14756366.2022.2135512","article-title":"Biological evaluation, docking studies, and in silico ADME prediction of some pyrimidine and pyridine derivatives as potential EGFRWT and EGFRT790M inhibitors","volume":"38","author":"Al-Warhi","year":"2023","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109476_bb0480","first-page":"1457","article-title":"Novel 2-(5-aryl-4,5-dihydropyrazol-1-yl)thiazol-4-one as EGFR inhibitors: synthesis, biological assessment and molecular docking insights","volume":"17","author":"Al-Warhi","year":"2023","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.bioorg.2026.109476_bb0485","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108581","article-title":"Investigating the multi-mechanistic anticancer effects of 4-bisarylurea thiouracil derivatives in breast cancer cells","volume":"162","author":"Fares","year":"2025","journal-title":"Bioorg. Chem."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004520682600012X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004520682600012X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T21:10:37Z","timestamp":1770066637000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004520682600012X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":97,"alternative-id":["S004520682600012X"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109476","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Expanding the chemical and therapeutic landscape of 5H-Indeno[1,2-b]pyridin-5-one derivatives: Novel anticancer activity, EGFR inhibition, and modulation of HIF\u2013VEGF and PI3K\/AKT\/mTOR pathways supported by computational insights","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109476","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109476"}}